Anti-CYP2C19 抗体 [EPR6576] - BSA and Azide free
Anti-CYP2C19 antibody [EPR6576] - BSA and Azide free
- RabMAb
- Recombinant
- 詳細を見る
Be the first to review this product! Submit a review
|
(1 Publication)
Rabbit Recombinant Monoclonal CP2CJ antibody. Carrier free. Suitable for WB, IHC-P and reacts with Mouse, Rat, Human samples. Cited in 1 publication.
別名を表示する
Cytochrome P450 2C19, (R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, CYPIIC17, CYPIIC19, Cytochrome P450-11A, Cytochrome P450-254C, Fenbendazole monooxygenase (4'-hydroxylating), Mephenytoin 4-hydroxylase, CYP2C19
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2C19 antibody [EPR6576] - BSA and Azide free (AB236063)
Immunohistochemical analysis of paraffin-embedded human liver tissue labelling CYP2C19 with ab137015 at 1/250 dilution.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab137015).
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2C19 antibody [EPR6576] - BSA and Azide free (AB236063)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human liver tissue sections labeling CYP2C19 with Purified ab137015 at 1 : 1000 dilution (0.49 μg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control : PBS instead of the primary antibody.Hematoxylinwas used as a counterstain.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab137015).
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2C19 antibody [EPR6576] - BSA and Azide free (AB236063)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Mouse liver tissue sections labeling CYP2C19 with Purified ab137015 at 1 : 1000 dilution (0.49 μg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control : PBS instead of the primary antibody.Hematoxylinwas used as a counterstain.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab137015).
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2C19 antibody [EPR6576] - BSA and Azide free (AB236063)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Rat liver tissue sections labeling CYP2C19 with Purified ab137015 at 1 : 1000 dilution (0.49 μg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control : PBS instead of the primary antibody.Hematoxylinwas used as a counterstain
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab137015).
- OI-RD Scanning
Unknown
OI-RD Scanning - Anti-CYP2C19 antibody [EPR6576] - BSA and Azide free (AB236063)
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
関連する標識済み抗体及び組成の異なる製品 (1)
-
Anti-CYP2C19 antibody [EPR6576]
Reactivity data
製品の詳細
ab236063 is the carrier-free version of ab137015.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
出荷温度及び保存条件
製品の状態
精製方法
バッファー組成
出荷温度
短期保存温度
長期保存温度
保管に関する情報
補足情報
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Cytochrome P450 2C19 is responsible for metabolizing drugs such as proton pump inhibitors antiepileptic drugs and some antidepressants. This enzyme is part of a larger enzyme family that contributes to the detoxification processes and biosynthesis of steroid hormones. It acts by catalyzing the oxidative transformation of compounds which influences drug activation and clearance. Its substrate specificity includes many significant pharmacological agents.
Pathways
CYP2C19 is integrally involved in drug metabolism pathways particularly the Phase I metabolism. It cooperates with enzymes like CYP2C9 and CYP3A4 within these pathways performing hydrolytic and oxidative reactions that transform lipophilic drugs into more water-soluble derivatives. Consequently this activity prepares compounds for further modification in Phase II metabolism facilitating excretion from the body.
製品プロトコール
- Visit the General protocols
- Visit the Troubleshooting
ターゲットの情報
文献 (1)
Recent publications for all applications. Explore the full list and refine your search
Developmental cell 53:9-26.e4 PubMed32197068
2020
Applications
Unspecified application
Species
Unspecified reactive species
Abcam product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com